Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Return to V2 Home
Search
INACTIVE COMPANY
  
My Lists

Xtent  (Stock symbol: XTNT )

125 Constitution Drive
 Menlo Park, CA 94025
 USA
 650.475.9400
Website Company Summary Management Team
Team
Management: Randolph E Campbell (CTO)
Outside board: Allan R Will (Split Rock Partners) ;  Michael L Eagle (Eli Lilly manufacturing) ;  Edward W Unkart (SurgRx CFO) ;  Patrick Latterell (Venrock Associates);  Michael Carusi (Advanced Technology Ventures);  Robert E Flaherty (Athena Diagnostics President/CEO/Chairman);  Arthur T Taylor (Kyphon sr. executive) ;  Christopher M Smith (Cochlear Americas President);  Hank A Plain (Xtent Chairman)
Company
Business description: XTENT, Inc. develops customizable drug-eluting stent (DES) systems for the treatment of coronary artery disease. XTENT's customizable DES systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.
Capital
Rounds: 4
Recent fundings: May 2006   Mar 2005
Capital raised: 75.0M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XTNT

Last Tweets

 

Last Mentions

Overview
Record updated: May 2009
Sector: Medical
Year Founded: 2002
Rounds: 4
Recent fundings: May 2006   Mar 2005
Capital raised: 75.0M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XTNT
©2003-2022 Link Silicon Valley LLC Home